Study of Tamoxifen and Raloxifene (STAR)

Known as: STAR, Study of Tamoxifen and Raloxifene 
Part of the National Surgical Adjuvant Breast and Bowel Project. A study to compare the efficacy of Tamoxifen to Raloxifene in prevention of primary… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2014
051019982014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Decision-making experts emphasize that understanding and using probabilistic information are important for making… (More)
Is this relevant?
2012
2012
Mammographic breast density is an established risk factor for breast cancer. However, results are inconclusive regarding its use… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
Many estrogen receptor (ER)-positive breast cancers respond well initially to endocrine therapies, but often develop resistance… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2010
2010
OBJECTIVE To compare the relative effects of conjugated equine estrogens (CEE), raloxifene, and tamoxifen therapies on cognition… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
PURPOSE To compare the effects of two selective estrogen receptor modulators, tamoxifen and raloxifene, on global and domain… (More)
Is this relevant?
Review
2009
Review
2009
  • V. Vogel
  • Expert review of anticancer therapy
  • 2009
In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
CONTEXT Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Selective estrogen receptor modulators (SERMs) such as tamoxifen are effective in the treatment of many estrogen receptor… (More)
Is this relevant?